These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

767 related items for PubMed ID: 11761458

  • 21. Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines.
    Virag P, Perde-Schrepler M, Fischer-Fodor E, Tatomir C, Dorneanu SA, Cernea VI, Irimie A.
    Anticancer Drugs; 2012 Nov; 23(10):1032-8. PubMed ID: 22614106
    [Abstract] [Full Text] [Related]

  • 22. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin.
    Fokkema E, Groen HJ, Helder MN, de Vries EG, Meijer C.
    Biochem Pharmacol; 2002 Jun 01; 63(11):1989-96. PubMed ID: 12093475
    [Abstract] [Full Text] [Related]

  • 23. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
    Martelli L, Di Mario F, Botti P, Ragazzi E, Martelli M, Kelland L.
    Biochem Pharmacol; 2007 Jun 30; 74(1):20-7. PubMed ID: 17466278
    [Abstract] [Full Text] [Related]

  • 24. Specificity of platinum-DNA adduct repair.
    Chaney SG, Vaisman A.
    J Inorg Biochem; 1999 Oct 30; 77(1-2):71-81. PubMed ID: 10626357
    [Abstract] [Full Text] [Related]

  • 25. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines.
    Noordhuis P, Laan AC, van de Born K, Losekoot N, Kathmann I, Peters GJ.
    Biochem Pharmacol; 2008 Jul 01; 76(1):53-61. PubMed ID: 18508032
    [Abstract] [Full Text] [Related]

  • 26. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
    Samimi G, Howell SB.
    Cancer Chemother Pharmacol; 2006 Jun 01; 57(6):781-8. PubMed ID: 16170571
    [Abstract] [Full Text] [Related]

  • 27. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers.
    Pendyala L, Kidani Y, Perez R, Wilkes J, Bernacki RJ, Creaven PJ.
    Cancer Lett; 1995 Nov 06; 97(2):177-84. PubMed ID: 7497460
    [Abstract] [Full Text] [Related]

  • 28. Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter.
    Helleman J, Burger H, Hamelers IH, Boersma AW, de Kroon AI, Stoter G, Nooter K.
    Cancer Biol Ther; 2006 Aug 06; 5(8):943-9. PubMed ID: 16775422
    [Abstract] [Full Text] [Related]

  • 29. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G, Kishimoto S, Manorek G, Breaux JK, Howell SB.
    Cancer Chemother Pharmacol; 2007 Feb 06; 59(3):301-12. PubMed ID: 16770583
    [Abstract] [Full Text] [Related]

  • 30. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
    Peters GJ, Van Moorsel CJ, Lakerveld B, Smid K, Noordhuis P, Comijn EC, Weaver D, Willey JC, Voorn D, Van der Vijgh WJ, Pinedo HM.
    Int J Oncol; 2006 Jan 06; 28(1):237-44. PubMed ID: 16328001
    [Abstract] [Full Text] [Related]

  • 31. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
    Stordal BK, Davey MW, Davey RA.
    Cancer Chemother Pharmacol; 2006 Aug 06; 58(2):256-65. PubMed ID: 16283310
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
    Kudo K, Gavin E, Das S, Amable L, Shevde LA, Reed E.
    Oncogene; 2012 Nov 01; 31(44):4718-24. PubMed ID: 22266871
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
    Li QQ, Yunmbam MK, Zhong X, Yu JJ, Mimnaugh EG, Neckers L, Reed E.
    Cell Mol Biol (Noisy-le-grand); 2001 Nov 01; 47 Online Pub():OL61-72. PubMed ID: 11936875
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY, Rogers PM, Kelland LR.
    Clin Cancer Res; 1995 Sep 01; 1(9):981-9. PubMed ID: 9816070
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Synthesis and activity of a trinuclear platinum complex: [{trans-PtCl(NH3)2}2mu-{trans-Pt(3-hydroxypyridine)2(H2N(CH2)6NH2)2}]Cl4 in ovarian cancer cell lines.
    Tayyem H, Huq F, Yu JQ, Beale P, Fisher K.
    ChemMedChem; 2008 Jan 01; 3(1):145-51. PubMed ID: 17963210
    [Abstract] [Full Text] [Related]

  • 40. Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models.
    Arzuman L, Beale P, Yu JQ, Proschogo N, Huq F.
    Anticancer Res; 2014 Dec 01; 34(12):7077-90. PubMed ID: 25503135
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.